Clinical Trials Directory

Trials / Completed

CompletedNCT01284309

A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

A Phase 1b, Randomized, Double-Masked, Parallel Group, Placebo Controlled Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
321 (actual)
Sponsor
Astellas Pharma Inc · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the affect of mirabegron on intraocular pressure (IOP) in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGMirabegronoral
DRUGPlacebooral

Timeline

Start date
2010-11-01
Primary completion
2011-02-01
Completion
2011-02-01
First posted
2011-01-27
Last updated
2013-12-11

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01284309. Inclusion in this directory is not an endorsement.